may also be obtained by accessing its website (http://www.usitc.gov). Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000.

Background: All dates and other information relating to this investigation remain the same as in the Commission’s notice of investigation and public hearing issued on May 23, 2018 and published in the Federal Register of May 25, 2018 (83 FR 24342).

By order of the Commission.
Issued: June 14, 2018.
Lisa Barton,
Secretary to the Commission.

[FR Doc. 2018–13176 Filed 6–19–18; 8:45 am]
BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Application: Fisher Clinical Services, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 20, 2018. Such persons may also file a written request for a hearing on the application on or before July 20, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on March 16, 2018, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106 applied to be registered as an importer of 1-(1-(2-Thienyl)cyclohexyl)pyrrolidine (7473), a basic class of controlled substance listed in schedule I.

The company plans to import the controlled substance in finished dosage form for testing and clinical trials purposes only.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under to 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: June 12, 2018.
John J. Martin,
Assistant Administrator.

[FR Doc. 2018–13224 Filed 6–19–18; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR Docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMRI Rensselaer, Inc</td>
<td>83 FR 5808</td>
<td>February 9, 2018</td>
</tr>
<tr>
<td>Stepan Company</td>
<td>83 FR 9029</td>
<td>March 2, 2018</td>
</tr>
<tr>
<td>Research Triangle Institute</td>
<td>83 FR 10523</td>
<td>March 9, 2018</td>
</tr>
<tr>
<td>Rhodes Technologies</td>
<td>83 FR 12407</td>
<td>March 21, 2018</td>
</tr>
<tr>
<td>Synthcon, LLC</td>
<td>83 FR 13141</td>
<td>March 27, 2018</td>
</tr>
<tr>
<td>National Center for Natural Products—Research NIDA MPROJECT</td>
<td>83 FR 13522</td>
<td>March 29, 2018</td>
</tr>
<tr>
<td>Insys Manufacturing LLC</td>
<td>83 FR 13522</td>
<td>March 29, 2018</td>
</tr>
<tr>
<td>Navinta LLC</td>
<td>83 FR 13521</td>
<td>March 29, 2018</td>
</tr>
</tbody>
</table>

Dated: June 12, 2018.
John J. Martin,
Assistant Administrator.

[FR Doc. 2018–13223 Filed 6–19–18; 8:45 am]
BILLING CODE 4410–09–P